Skip to main content

Table 5 Use of methotrexate at baseline

From: Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation

  Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis a Other b Total
N [N missing] 190 [1] 43 [0] 44 [0] 35 [0] 19 [12] 331 [13]
Taking methotrexate       
   No, n (%) 71 (37.4%) 38 (88.4%) 27 (61.4%) 31 (88.6%) 11 (57.9%) 178 (53.8%)
   Unsure, n (%) 1 (0.5%) 2 (4.7%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 4 (1.2%)
   Yes, n (%) 118 (62.1%) 3 (7.0%) 16 (36.4%) 4 (11.4%) 8 (42.1%) 149 (45.0%)
Route of administration       
   Tablets, n (%) 97 (82.2%) 3 (100.0%) 11 (68.8%) 3 (75.0%) 6 (75.0%) 120 (80.5%)
   Injection, n (%) 21 (17.8%) 0 (0.0%) 5 (31.2%) 1 (25.0%) 2 (25.0%) 29 (19.5%)
Weekly dose       
   N [N missing] 116 [2] 3 [0] 16 [0] 4 [0] 7 [1] 146 [3]
   Mean (SD) 16.6 (6.8) 17.5 (2.5) 15.6 (7.3) 16.2 (9.7) 13.6 (8.9) 16.4 (6.9)
   Range 2.5-30.0 15.0-20.0 2.5-25.0 2.5-25.0 2.5-25.0 2.5-30.0
Feedback received       
   Yes, n (% of not taking) 40 (56.3%) 21 (55.3%) 19 (70.4%) 16 (51.6%) 5 (45.5%) 101 (56.7%)
Ever prescribed c       
   No, n (%) 1 (2.5%) 18 (85.7%) 0 (0.0%) 5 (31.2%) 1 (20.0%) 25 (24.8%)
   Unsure, n (%) 1 (2.5%) 1 (4.8%) 0 (0.0%) 1 (6.2%) 0 (0.0%) 3 (3.0%)
   Yes, n (%) 38 (95.0%) 2 (9.5%) 19 (100.0%) 10 (62.5%) 4 (80.0%) 73 (72.3%)
Reason stopped d       
   Lack of effect, n (%) 6 (15.8%) 1 (50.0%) 1 (5.3%) 4 (40.0%) 0 (0.0%) 12 (16.4%)
   Side effects, n (%) 27 (71.1%) 1 (50.0%) 16 (84.2%) 5 (50.0%) 3 (75.0%) 52 (71.2%)
   Doctor stopped, n (%) 5 (13.2%) 0 (0.0%) 2 (10.5%) 1 (10.0%) 1 (25.0%) 9 (12.3%)
   Unsure, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
  1. a Twenty-five patients (71.4%) with psoriasis were also using creams for the condition at baseline, but none of the patients had undergone phototherapy treatment.
  2. b Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?
  3. c Data for feedback responders (Respondents answering "no" to the question " Are you taking methotrexate" at baseline and providing feedback on any previous use)
  4. d Data for feedback responders ever prescribed methotrexate (Feedback respondents answering "yes" to the question " Have you ever been prescribed methotrexate")